Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Antiplatelet therapy in cardiovascular disease / / edited by Ron Waksman, Paul A. Gurbel, Michael A. Gaglia, Jr
| Antiplatelet therapy in cardiovascular disease / / edited by Ron Waksman, Paul A. Gurbel, Michael A. Gaglia, Jr |
| Pubbl/distr/stampa | Chichester, West Sussex, United Kingdom : , : John Wiley & Sons, , 2014 |
| Descrizione fisica | 1 online resource (349 p.) |
| Disciplina | 616.1/061 |
| Soggetto topico |
Cardiovascular system - Diseases
Cardiovascular system - Diseases - Prevention |
| ISBN |
1-118-49402-4
1-118-49398-2 1-118-49401-6 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antiplatelet Therapy in Cardiovascular Disease; Copyright; Contents; List of Contributors; Foreword; Preface; Section I Platelet Biology and Pathophysiology; 1 Platelet Pathophysiology and its Role in Thrombosis; Role of platelets during initiation of atherosclerosis and plaque formation; Role of platelets in thrombosis; References; 2 Platelet Receptors and Drug Targets: COX-1; Structure, expression, and catalytic activity of platelet COX-1; Functional role of platelet COX -1; Genetic polymorphisms of COX-1 and COX-2 expression in platelets
Platelet COX-1 as a target for antithrombotic therapyInteraction between aspirin and naNSAIDs at the level of platelet COX-1; In vitro and in vivo evidence for aspirin/naNSAID interaction; Concluding remarks; References; 3 Platelet Receptors and Drug Targets: P2Y12; P2 receptors; Roles of adenine nucleotides in platelet function; P2Y12; Conclusions; References; 4 Platelet Receptors and Drug Targets: GP IIb/IIIa; Introduction; Biology of the receptor; Glycoprotein IIb/IIIa receptor in platelet physiology; Platelet aggregation phase; "Inside-out" and "outside-in" GPIIb/IIIa signaling phenomenon Glycoprotein IIb/IIIa receptor and thrombus formationGlycoprotein IIb/IIIa receptor antagonists; Intravenous versus oral preparations: clinical aspects; Acknowledgment; References; 5 Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets; Introduction; Protease-activated receptor 1 (PAR1); References; 6 Role of Inflammation and Hypercoagulability in Thrombosis; References; Section II Platelet Function Tests; 7 Light Transmission Aggregometry; Technique; References; 8 Vasodilator-Stimulated Phosphoprotein (VASP) Assay; Introduction; The VASP index assay VASP index and clinical eventsAlteration of antiplatelet therapy based on the VASP index; VASP index and new oral antiplatelet agents; Conclusions; References; 9 VerifyNow P2Y12 and Plateletworks Assays; Introduction; Verifynow P2Y12; Plateletworks; Validity of the test in measuring antiplatelet effect and its association with clinical outcomes; Conclusion; References; 10 Multiplate Analyzer; Historical background; Principles of the Multiplate® analyzer; Advantages; Disadvantages; Clinical studies in cardiovascular medicine; Studies in cardiovascular surgery Consensus definitions and cutoff values concerning platelet reactivitySummary; Acknowledgment; References; 11 Shear Stress-Based Platelet Function Tests; PFA-100; IMPACT-R; References; 12 Thrombelastography and Other Novel Techniques; Novel techniques; T2 magnetic resonance (T2MR); Shear-induced platelet aggregation assays; References; Section III Antiplatelet pharmacology; 13 Aspirin; Mode of antiplatelet action; Time dependency of inhibition of platelet function by aspirin; Dose-dependent inhibition of platelet function by aspirin; Negative interactions with other drugs Positive interactions with other drugs |
| Record Nr. | UNINA-9910140272703321 |
| Chichester, West Sussex, United Kingdom : , : John Wiley & Sons, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiplatelet therapy in cardiovascular disease / / edited by Ron Waksman, Paul A. Gurbel, Michael A. Gaglia, Jr
| Antiplatelet therapy in cardiovascular disease / / edited by Ron Waksman, Paul A. Gurbel, Michael A. Gaglia, Jr |
| Pubbl/distr/stampa | Chichester, West Sussex, United Kingdom : , : John Wiley & Sons, , 2014 |
| Descrizione fisica | 1 online resource (349 p.) |
| Disciplina | 616.1/061 |
| Soggetto topico |
Cardiovascular system - Diseases
Cardiovascular system - Diseases - Prevention |
| ISBN |
1-118-49402-4
1-118-49398-2 1-118-49401-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antiplatelet Therapy in Cardiovascular Disease; Copyright; Contents; List of Contributors; Foreword; Preface; Section I Platelet Biology and Pathophysiology; 1 Platelet Pathophysiology and its Role in Thrombosis; Role of platelets during initiation of atherosclerosis and plaque formation; Role of platelets in thrombosis; References; 2 Platelet Receptors and Drug Targets: COX-1; Structure, expression, and catalytic activity of platelet COX-1; Functional role of platelet COX -1; Genetic polymorphisms of COX-1 and COX-2 expression in platelets
Platelet COX-1 as a target for antithrombotic therapyInteraction between aspirin and naNSAIDs at the level of platelet COX-1; In vitro and in vivo evidence for aspirin/naNSAID interaction; Concluding remarks; References; 3 Platelet Receptors and Drug Targets: P2Y12; P2 receptors; Roles of adenine nucleotides in platelet function; P2Y12; Conclusions; References; 4 Platelet Receptors and Drug Targets: GP IIb/IIIa; Introduction; Biology of the receptor; Glycoprotein IIb/IIIa receptor in platelet physiology; Platelet aggregation phase; "Inside-out" and "outside-in" GPIIb/IIIa signaling phenomenon Glycoprotein IIb/IIIa receptor and thrombus formationGlycoprotein IIb/IIIa receptor antagonists; Intravenous versus oral preparations: clinical aspects; Acknowledgment; References; 5 Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets; Introduction; Protease-activated receptor 1 (PAR1); References; 6 Role of Inflammation and Hypercoagulability in Thrombosis; References; Section II Platelet Function Tests; 7 Light Transmission Aggregometry; Technique; References; 8 Vasodilator-Stimulated Phosphoprotein (VASP) Assay; Introduction; The VASP index assay VASP index and clinical eventsAlteration of antiplatelet therapy based on the VASP index; VASP index and new oral antiplatelet agents; Conclusions; References; 9 VerifyNow P2Y12 and Plateletworks Assays; Introduction; Verifynow P2Y12; Plateletworks; Validity of the test in measuring antiplatelet effect and its association with clinical outcomes; Conclusion; References; 10 Multiplate Analyzer; Historical background; Principles of the Multiplate® analyzer; Advantages; Disadvantages; Clinical studies in cardiovascular medicine; Studies in cardiovascular surgery Consensus definitions and cutoff values concerning platelet reactivitySummary; Acknowledgment; References; 11 Shear Stress-Based Platelet Function Tests; PFA-100; IMPACT-R; References; 12 Thrombelastography and Other Novel Techniques; Novel techniques; T2 magnetic resonance (T2MR); Shear-induced platelet aggregation assays; References; Section III Antiplatelet pharmacology; 13 Aspirin; Mode of antiplatelet action; Time dependency of inhibition of platelet function by aspirin; Dose-dependent inhibition of platelet function by aspirin; Negative interactions with other drugs Positive interactions with other drugs |
| Record Nr. | UNINA-9910819754603321 |
| Chichester, West Sussex, United Kingdom : , : John Wiley & Sons, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Calcium Antagonists and Microcirculation : : Symposium at the 4th World Congress for Microcirculation, Tokyo, July 1987: Proceedings / / editor, M. Steinhausen
| Calcium Antagonists and Microcirculation : : Symposium at the 4th World Congress for Microcirculation, Tokyo, July 1987: Proceedings / / editor, M. Steinhausen |
| Autore | Steinhausen M |
| Pubbl/distr/stampa | Basel : , : S. Karger, , 1988 |
| Descrizione fisica | 1 online resource (VIII + 120 pages) : : 52 figures, 3 tables |
| Disciplina | 616.1/061 |
| Altri autori (Persone) | SteinhausenMichael |
| Soggetto topico |
Cardiovascular System
Microcirculation |
| ISBN | 3-318-04073-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910158700403321 |
Steinhausen M
|
||
| Basel : , : S. Karger, , 1988 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cardiotoxicity of non-cardiovascular drugs [[electronic resource] /] / editor, Giorgio Minotti
| Cardiotoxicity of non-cardiovascular drugs [[electronic resource] /] / editor, Giorgio Minotti |
| Pubbl/distr/stampa | Chichester, West Sussex, : Wiley, 2010 |
| Descrizione fisica | 1 online resource (362 p.) |
| Disciplina | 616.1/061 |
| Altri autori (Persone) | MinottiGiorgio |
| Soggetto topico | Cardiovascular toxicology |
| ISBN |
1-282-54804-2
9786612548048 0-470-66037-6 0-470-66038-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Machine generated contents note: List of Contributors -- 1. Mitochondrial Dysfunction In Cell Injury and Cardiotoxicity -- Fabio Di Lisa, Martina Semenzato, Andrea Carpi, Sara Menazza, Nina Kaludercic, Roberta Menabò, Marcella Canton -- 2. Cardiovascular Liabilities of Drugs: Regulatory Aspects -- Claudio Arrigoni -- 3. Cellular Mechanisms, Molecular Targets, and Structure-Function Relationships In Drug-Induced Arrhythmias: The Case Of Antihistamines, Psychoactive Drugs, and Antimicrobial Agents -- Maria Virginia Soldovieri and Maurizio Taglialatela -- 4. Cardiovascular Toxicity of Antitumor Drugs: Dimensions of the Problem in Children -- Rebecca Scully, Louis Pruitt, Steven E. Lipshultz -- 5. Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings -- Joseph R. Carver and Chaitali J. Desai -- 6. Diagnostic Aspects of Cardiovascular Toxicity of Antitumor Drugs -- Michael S. Ewer, Thomas M. Suter -- 7. Cardiovascular Toxicity of Antitumor Drugs: Translating Molecular Mechanisms into Clinical Facts -- Pierantonio Menna, Emanuela Salvatorelli, Carlo Salsano, Luca Gianni*, and Giorgio Minotti -- 8. NSAID Action and the Foundations for Cardiovascular Toxicity -- Anna L. Blobaum and Lawrence J. Marnett -- 9. Cardiovascular toxicities of NSAIDS: Epidemiologic aspects -- Antonio González-Pe;rez, Luis Alberto Garci;a Rodriguez -- 10. Cardiovascular Toxicities of Life-Saving Drugs: Antiviral Therapy -- James J. Kohler & William Lewis. |
| Record Nr. | UNINA-9910140586903321 |
| Chichester, West Sussex, : Wiley, 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cardiotoxicity of non-cardiovascular drugs [[electronic resource] /] / editor, Giorgio Minotti
| Cardiotoxicity of non-cardiovascular drugs [[electronic resource] /] / editor, Giorgio Minotti |
| Pubbl/distr/stampa | Chichester, West Sussex, : Wiley, 2010 |
| Descrizione fisica | 1 online resource (362 p.) |
| Disciplina | 616.1/061 |
| Altri autori (Persone) | MinottiGiorgio |
| Soggetto topico | Cardiovascular toxicology |
| ISBN |
1-282-54804-2
9786612548048 0-470-66037-6 0-470-66038-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Machine generated contents note: List of Contributors -- 1. Mitochondrial Dysfunction In Cell Injury and Cardiotoxicity -- Fabio Di Lisa, Martina Semenzato, Andrea Carpi, Sara Menazza, Nina Kaludercic, Roberta Menabò, Marcella Canton -- 2. Cardiovascular Liabilities of Drugs: Regulatory Aspects -- Claudio Arrigoni -- 3. Cellular Mechanisms, Molecular Targets, and Structure-Function Relationships In Drug-Induced Arrhythmias: The Case Of Antihistamines, Psychoactive Drugs, and Antimicrobial Agents -- Maria Virginia Soldovieri and Maurizio Taglialatela -- 4. Cardiovascular Toxicity of Antitumor Drugs: Dimensions of the Problem in Children -- Rebecca Scully, Louis Pruitt, Steven E. Lipshultz -- 5. Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings -- Joseph R. Carver and Chaitali J. Desai -- 6. Diagnostic Aspects of Cardiovascular Toxicity of Antitumor Drugs -- Michael S. Ewer, Thomas M. Suter -- 7. Cardiovascular Toxicity of Antitumor Drugs: Translating Molecular Mechanisms into Clinical Facts -- Pierantonio Menna, Emanuela Salvatorelli, Carlo Salsano, Luca Gianni*, and Giorgio Minotti -- 8. NSAID Action and the Foundations for Cardiovascular Toxicity -- Anna L. Blobaum and Lawrence J. Marnett -- 9. Cardiovascular toxicities of NSAIDS: Epidemiologic aspects -- Antonio González-Pe;rez, Luis Alberto Garci;a Rodriguez -- 10. Cardiovascular Toxicities of Life-Saving Drugs: Antiviral Therapy -- James J. Kohler & William Lewis. |
| Record Nr. | UNINA-9910808207503321 |
| Chichester, West Sussex, : Wiley, 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cardiovascular diseases : from molecular pharmacology to evidence-based therapeutics / / Y. Robert Li
| Cardiovascular diseases : from molecular pharmacology to evidence-based therapeutics / / Y. Robert Li |
| Autore | Li Robert Y. |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : John Wiley & Sons Inc., , 2015 |
| Descrizione fisica | 1 online resource (504 p.) |
| Disciplina | 616.1/061 |
| Soggetto topico |
Cardiovascular system - Diseases - Chemotherapy
Cardiovascular system - Diseases - Diagnosis |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-118-88994-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Title Page; Copyright Page; Contents; Preface; List of Abbreviations; Unit I General Introduction; Chapter 1 Introduction to Cardiovascular Diseases; 1.1 Overview; 1.2 Definition of Cardiovascular Diseases; 1.3 Classification of Cardiovascular Diseases; 1.3.1 Classification Based on Anatomical Location; 1.3.2 Classification Based on the Involvement of Atherosclerosis; 1.3.3 Total Cardiovascular Diseases and ICD-10 Classification; 1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases; 1.4.1 NCDs and Cardiovascular Diseases: The Global Status
1.4.2 The Status of Cardiovascular Diseases in the United States1.4.3 The Status of Cardiovascular Diseases in China; 1.5 Risk Factors of Cardiovascular Diseases; 1.5.1 Classification of Cardiovascular Disease Risk Factors; 1.5.2 Major Cardiovascular Disease Risk Factors and Their Impact; 1.6 Prevention and Control of Cardiovascular Diseases; 1.6.1 The UN High-Level Meeting and Tackling Cardiovascular Diseases at the Global Level; 1.6.2 The World Heart Federation Call to Action to Prevent and Control Cardiovascular Diseases 1.6.3 The AHA 2010 Health Impact Goal, 2020 Health Impact Goal, and Ideal Cardiovascular Health1.6.4 US DHSS "Million Hearts" Initiative; 1.7 Cardiovascular Risk Prediction and Evidence-based Treatments; 1.7.1 Cardiovascular Risk Prediction; 1.7.2 Evidence-Based Treatments; 1.8 Summary of Chapter Key Points; 1.9 Self-Assessment Questions; References; Chapter 2 Introduction to Principles of Pharmacology; 2.1 Overview; 2.2 Definitions and History; 2.2.1 What Is Pharmacology?; 2.2.2 Definitions of Related Terms; 2.2.3 A Brief History of Pharmacology 2.3 Pharmacological Paradigm: the Central Dogma in Pharmacology2.3.1 Drug Names, Sources, Preparations, and Administration; 2.3.2 Pharmacokinetics; 2.3.3 Pharmacodynamics; 2.3.4 Drug Toxicity; 2.3.5 Pharmacogenetics and Pharmacogenomics; 2.4 Principles of Drug Discovery, Development, and Regulation; 2.4.1 Definitions; 2.4.2 The Paradigm of Drug Creation and Survival; 2.4.3 The FDA Drug Review and Approval Process; 2.5 Pharmacology Subspecialties; 2.6 Introduction to Cardiovascular Pharmacology; 2.6.1 Definition and Scope; 2.6.2 New Developments and Challenges 2.6.3 Systems Pharmacology in the Management of Cardiovascular Diseases2.6.4 Polypill for the Management of Cardiovascular Diseases; 2.6.5 Protein Therapeutics of Cardiovascular Diseases; 2.6.6 Gene Therapy of Cardiovascular Diseases; 2.6.7 Stem Cell Therapy of Cardiovascular Diseases; 2.7 Summary of Chapter Key Points; 2.8 Self-Assessment Questions; References; Unit II Dyslipidemias; Chapter 3 Overview of Dyslipidemias and Drug Therapy; 3.1 Introduction; 3.2 Lipoprotein Metabolism; 3.2.1 Definition, Structure, and Classification of Lipoproteins 3.2.2 Metabolic Pathways of Lipoproteins and Drug Therapy |
| Record Nr. | UNINA-9910460135303321 |
|
Li Robert Y.
|
||
| Hoboken, New Jersey : , : John Wiley & Sons Inc., , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cardiovascular diseases : from molecular pharmacology to evidence-based therapeutics / / Y. Robert Li
| Cardiovascular diseases : from molecular pharmacology to evidence-based therapeutics / / Y. Robert Li |
| Autore | Li Robert Y. |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : John Wiley & Sons Inc., , 2015 |
| Descrizione fisica | 1 online resource (504 pages) : illustrations (some color) |
| Disciplina | 616.1/061 |
| Soggetto topico |
Cardiovascular system - Diseases - Chemotherapy
Cardiovascular system - Diseases - Diagnosis |
| ISBN |
1-118-88994-0
1-118-88991-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910795975103321 |
|
Li Robert Y.
|
||
| Hoboken, New Jersey : , : John Wiley & Sons Inc., , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cardiovascular diseases : from molecular pharmacology to evidence-based therapeutics / / Y. Robert Li
| Cardiovascular diseases : from molecular pharmacology to evidence-based therapeutics / / Y. Robert Li |
| Autore | Li Robert Y. |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : John Wiley & Sons Inc., , 2015 |
| Descrizione fisica | 1 online resource (504 pages) : illustrations (some color) |
| Disciplina | 616.1/061 |
| Soggetto topico |
Cardiovascular system - Diseases - Chemotherapy
Cardiovascular system - Diseases - Diagnosis |
| ISBN |
1-118-88994-0
1-118-88991-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910819764403321 |
|
Li Robert Y.
|
||
| Hoboken, New Jersey : , : John Wiley & Sons Inc., , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical Aspects of Calcium Entry Blockers / / editor, P.A. van Zwieten
| Clinical Aspects of Calcium Entry Blockers / / editor, P.A. van Zwieten |
| Autore | van Zwieten P.A |
| Pubbl/distr/stampa | Basel : , : S. Karger, , 1989 |
| Descrizione fisica | 1 online resource (XII + 200 pages) : : 14 figures, 1 in color, 15 tables |
| Disciplina | 616.1/061 |
| Altri autori (Persone) | ZwietenP. A. van |
| Collana | Progress in Basic and Clinical Pharmacology |
| Soggetto topico |
Pharmacology
Biochemistry Enzymology Toxicology |
| ISBN | 3-318-04083-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910158699203321 |
|
van Zwieten P.A
|
||
| Basel : , : S. Karger, , 1989 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Journal of cardiovascular pharmacology
| Journal of cardiovascular pharmacology |
| Pubbl/distr/stampa | New York, : Raven Press |
| Disciplina | 616.1/061 |
| ISSN | 0160-2446 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-990008986660403321 |
| New York, : Raven Press | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||